Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul 18;16(14):2571.
doi: 10.3390/cancers16142571.

Chemotherapy-Induced Peripheral Neuropathy (CIPN): A Narrative Review and Proposed Theoretical Model

Kimberley T Lee  1 , Hailey W Bulls  2 , Aasha I Hoogland  3 , Brian W James  4 , Claudia B Colon-Echevarria  5 , Heather S L Jim  3
Affiliations
Review

Chemotherapy-Induced Peripheral Neuropathy (CIPN): A Narrative Review and Proposed Theoretical Model

Kimberley T Lee et al. Cancers (Basel). .

Abstract

Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating symptom experienced by cancer survivors. Despite the burden of CIPN-related symptoms, interventions remain limited.

Objectives: This narrative review seeks to propose a framework for CIPN predisposing, precipitating, and perpetuating factors (3Ps), which will provide a foundation for future research and clinical interventions aimed at mitigating CIPN-related symptoms and morbidity.

Methods: A comprehensive literature search was performed using PubMed, guided by keywords related to "chemotherapy-induced peripheral neuropathy." Studies were limited to those with full text available in English.

Results: Predisposing factors outlined in this framework, such as older age and comorbid conditions, can be used to identify patients who have a higher risk of developing CIPN. The major precipitating factor of CIPN is the delivery of chemotherapy to peripheral nerves, which may be mitigated via cryotherapy or compression therapy during chemotherapy. Perpetuating factors can offer insight into psychological, cognitive, and behavioral modifications that could be treatment targets for CIPN management.

Conclusion: The proposed 3P model can guide the development of effective interventions for CIPN by suggesting modifiable psychological and behavioral treatment targets that may mitigate the impact of CIPN for cancer patients.

Keywords: cancer survivorship; chemotherapy-induced peripheral neuropathy; theoretical model.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
3P model of chemotherapy-included peripheral neuropathy (Created using Biorender).
Figure 2
Figure 2
Potential applications of 3P CIPN model (Created using Biorender).
See this image and copyright information in PMC

References

    1. Hershman D.L., Lacchetti C., Dworkin R.H., Lavoie Smith E.M., Bleeker J., Cavaletti G., Chauhan C., Gavin P., Lavino A., Lustberg M.B., et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 2014;32:1941–1967. doi: 10.1200/JCO.2013.54.0914. - DOI - PubMed
    1. Starobova H., Vetter I. Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy. Front. Mol. Neurosci. 2017;10:174. doi: 10.3389/fnmol.2017.00174. - DOI - PMC - PubMed
    1. Marshall T.F., Zipp G.P., Battaglia F., Moss R., Bryan S. Chemotherapy-induced-peripheral neuropathy, gait and fall risk in older adults following cancer treatment. J. Cancer Res. Pract. 2017;4:134–138. doi: 10.1016/j.jcrpr.2017.03.005. - DOI
    1. Hershman D.L., Weimer L.H., Wang A., Kranwinkel G., Brafman L., Fuentes D., Awad D., Crew K.D. Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res. Treat. 2011;125:767–774. doi: 10.1007/s10549-010-1278-0. - DOI - PubMed
    1. Lyman G.H. Impact of chemotherapy dose intensity on cancer patient outcomes. J. Natl. Compr. Cancer Netw. 2009;7:99–108. doi: 10.6004/jnccn.2009.0009. - DOI - PubMed

LinkOut - more resources